Search Results

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) today announced that on December 16, 2022, Altria Group, Inc. (“Altria”) notified the Company that its wholly owned subsidiary, Altria Summit LLC, relinquished a warrant to subscribe for and purchase up to 84,243,223 common shares of the Company at a per share exercise price of C$19.00.

Respira Technologies, Inc. (“Respira”), is pleased to announce Brian W. Quigley, a sixteen year veteran of Altria Group Inc., is joining Respira’s management

Cronos Group Inc. today confirmed that it is engaged in discussions concerning a potential investment by Altria Group Inc. (NYSE: MO) (“Altria Group”) in Cronos Group.

22nd Century Group, Inc. announced that on May 1, 2018, a federal court ordered Altria, R.J. Reynolds Tobacco, Lorillard, and Philip Morris USA to issue statements to correct marketing that deliberately deceived the public about the addictiveness and health risks of smoking.

Statement of Matthew L. Myers, President, Campaign for Tobacco-Free Kids

Cronos Group Inc. is pleased to announce that the meeting materials for a special meeting of holders of common shares of the Company to be held on February 21, 2019, including the management proxy circular dated December 31, 2018, prepared in connection with the proposed C$2.4 billion equity investment by Altria Group, Inc. in Cronos Group previously announced on December 7, 2018, have been mailed to Shareholders and filed with the relevant Canadian securities regulators.

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) today announces its 2022 third quarter business results.

Lexaria Bioscience Corp., a global innovator in drug delivery platforms is pleased to announce that independent review board approval has now been received for human clinical nicotine study NIC-H22-1, and that human dosing will begin soon.